Analyst’s Disclosure:I/we have a beneficial long position in the shares of AVGO either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any in ...

Core Viewpoint - The article discusses Lockheed Martin (LMT) and presents a perspective that it is currently a hold position for investors [1]. Group 1 - The author has previously analyzed Lockheed Martin and expressed a cautious stance on its investment potential [1]. - The article indicates a focus on the tech sector and highlights the author's educational background in finance [1]. - The author emphasizes core values such as excellence, integrity, transparency, and respect as essential for long-term success [1]. Group 2 - There is an invitation for readers to provide constructive criticism and feedback to improve the quality of the analysis [1].

Toronto, Ontario--(Newsfile Corp. - August 11, 2025) - Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FSE: 0K91) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, announces that further to its press release dated June 27, 2025, the Company will be seeking shareholder approval of its non-brokered private placement of class A multiple voting shares ("MVS") for aggregate gross proceeds of up to $600 (the "Offer ...

Trump rings the opening bell on the trading floor of the New York Stock Exchange (NYSE) on December 12, 2024 after being named TIME’s “Person of the Year."Spencer Platt/Getty ImagesThe Trump administration is teeing up what could be the biggest shakeup in U.S. housing finance since the 2008 crisis—a pair of IPOs that might value Fannie Mae and Freddie Mac at a combined $500 billion. The plan, which was first reported by The Wall Street Journal and is still being finalized by the administration, would see th ...

I last covered the Reaves Utility Income Trust (NYSE: UTG ) CEF on May 4 in an article titled "UTG: For Those Tired Of The Tariff Rollercoaster". I rated UTG as aAs you can tell, our core style is to provide actionable and unambiguous ideas from our independent research. If you share this investment style, check out Envision Early Retirement. It provides at least 1x in-depth articles per week on such ideas.We have helped our members not only to beat S&P 500 but also avoid heavy drawdowns despite the extreme ...

Since my last analysis on Civitas Resources, Inc. (NYSE: CIVI ), which was back during the worst period of the Trump administration tariffs, the stock has advanced significantly, posting a total return of 15.72%. With theAs a detail-oriented investor with a strong foundation in finance and business writing, I focus on analyzing undervalued and disliked companies or industries that have strong fundamentals and good cash flows. I have a particular interest in sectors such as Oil&Gas and consumer goods. Basica ...

Core Viewpoint - Marvel Biosciences Corp. has awarded 142,987 deferred share units (DSUs) to two directors as a form of compensation instead of cash payment, with the DSUs set to vest on July 31, 2026 [1][2]. Group 1: Company Overview - Marvel Biosciences Corp. is a Calgary-based pre-clinical stage pharmaceutical development biotechnology company [3]. - The company is developing MB-204, a novel fluorinated derivative of the anti-Parkinson's drug Istradefylline, which is the only clinically approved adenosine A2a antagonist [3]. - There is growing scientific evidence suggesting that drugs blocking the adenosine A2a receptor, like MB-204, may be effective in treating various neurological diseases, including autism, depression, and Alzheimer's Disease [3]. - The company is also exploring the potential of MB-204 in addressing neurodevelopmental disorders such as Rett Syndrome and Fragile X Syndrome to broaden its therapeutic applications [3]. Group 2: Financial Details - The deemed value of the awarded DSUs is calculated at $0.16 per share based on the volume-weighted average price (VWAP) of the company's common shares on the TSX Venture Exchange as of July 31, 2025 [2]. - Vested DSUs will be settled upon the directors' separation from the company and will expire 365 days after such separation [2].

Financial Performance - For the six months ended June 30, 2025, general and administrative expenses decreased to $0.27 million from $0.31 million in the same period of 2024 [2] - The net loss for the six months ended June 30, 2025, was $0.30 million ($nil loss per share), compared to a net loss of $0.34 million ($nil loss per share) for the same period in 2024 [2] - As of June 30, 2025, the company had cash of $0.02 million [2] Operational Developments - The company is working with ADT Environmental & Mineral Consultants and Global Resource Engineering to apply for permits to build a heap-leach processing pilot plant and a starter pit at the South Jumbo area in Utah, with a resource estimate of 214,565 oz M&I Au identified [3] - The company has engaged Gardiner Brothers Drilling Inc. to drill a water well near the processing facility, which will supply water for a large-scale operation [4] Company Overview - Gold Springs Resource Corp. focuses on the exploration and expansion of gold and silver resources at its Gold Springs project located on the border of Nevada and Utah, USA, in the Great Basin, a prominent mining jurisdiction [6]

Group 1: Elite Pharmaceuticals Inc. (ELTP) - ELTP is a manufacturer of generic drugs, focusing on controlled-release products which require higher manufacturing skills and vertical integration, differentiating itself in a price-sensitive market [2] - The company holds strong positions in the mixed Amphetamine Immediate Release (IR) and Extended Release (ER) markets, with significant growth driven by the ADHD market [3][6] - According to IQVIA data, ELTP commands approximately 20% of the $400 million generic Adderall IR market and 16% of the $800 million Adderall ER market [4] - In Q4 fiscal 2025, total revenues reached approximately $31.9 million, a 78.3% increase from $17.9 million in the previous year, with operating income rising to roughly $11.2 million from $3.7 million [5] - ELTP entered the lisdexamfetamine (Vyvanse generic) market in early 2025, capturing an estimated 8-10% market share despite competition [6] - The company experienced a pull-back in stock price post-earnings due to a $7.2 million warrant charge affecting EPS and increased competition in the ADHD generic space [7][8] Group 2: TSS, Inc. (TSSI) - TSSI's core business includes systems integration, facilities management, and IT procurement services, with a focus on AI-enabled computer racks [12][13] - The company reported a sales growth of 262% to $44 million in recent Q2, raising its 2025 adjusted EBITDA growth guidance from at least 50% to at least 75% [13] - Despite strong growth, TSSI's stock has pulled back nearly 30%, attributed to investor expectations for better leverage and elevated depreciation expenses from facility build-out [14] - TSSI began production at a new 213,000-square-foot facility in Georgetown, TX, optimized for high-volume AI rack integration, with management expecting profitability within a two-year payback period [15] - The stock is currently trading at a trailing EV/Sales multiple of 1.84x, which is reasonable for a business with multi-year sales visibility and proven growth [16][18]

Group 1 - Cronos Group Inc. (NASDAQ: CRON) stock price increased by 15% on news that President Trump’s administration will consider rescheduling cannabis in the coming weeks [1] - The announcement has implications for Canadian cannabis licensed producers (LPs) and U.S. cannabis Multi-State Operators [1] Group 2 - The article is part of a monthly report on the cannabis industry, highlighting the author's expertise in technical stock analysis, option strategies, small cap strategies, and emerging markets [1]